CO2024007013A2 - Isoxazolidinas como inhibidores de ripk1 y uso de estas - Google Patents

Isoxazolidinas como inhibidores de ripk1 y uso de estas

Info

Publication number
CO2024007013A2
CO2024007013A2 CONC2024/0007013A CO2024007013A CO2024007013A2 CO 2024007013 A2 CO2024007013 A2 CO 2024007013A2 CO 2024007013 A CO2024007013 A CO 2024007013A CO 2024007013 A2 CO2024007013 A2 CO 2024007013A2
Authority
CO
Colombia
Prior art keywords
isoxazolidines
inhibitors
ripk1
ripk1 inhibitors
kinase
Prior art date
Application number
CONC2024/0007013A
Other languages
English (en)
Inventor
Elisabeth Defossa
Kurt Ritter
Uwe Heinelt
Perez Maria Mendez
Nils Rackelmann
Hauke Szillat
Gernot Zech
Hans Matter
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CO2024007013A2 publication Critical patent/CO2024007013A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación se refiere a isoxazolidinas y su uso como inhibidores de la proteína··cinasa 1 que interacciona con receptores, por ejemplo, en el tratamiento de enfermedades y trastornos mediados por la cinasa RIP 1.
CONC2024/0007013A 2021-11-11 2024-05-31 Isoxazolidinas como inhibidores de ripk1 y uso de estas CO2024007013A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21315242 2021-11-11
PCT/EP2022/081226 WO2023083847A1 (en) 2021-11-11 2022-11-09 Isoxazolidines as ripk1 inhibitors and use thereof

Publications (1)

Publication Number Publication Date
CO2024007013A2 true CO2024007013A2 (es) 2024-07-18

Family

ID=78916777

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0007013A CO2024007013A2 (es) 2021-11-11 2024-05-31 Isoxazolidinas como inhibidores de ripk1 y uso de estas

Country Status (12)

Country Link
US (2) US11897876B2 (es)
EP (1) EP4430037A1 (es)
KR (1) KR20240099451A (es)
CN (1) CN118510775A (es)
AR (1) AR127640A1 (es)
AU (1) AU2022388696A1 (es)
CA (1) CA3237975A1 (es)
CO (1) CO2024007013A2 (es)
IL (1) IL312739A (es)
MX (1) MX2024005777A (es)
TW (1) TW202340182A (es)
WO (1) WO2023083847A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118510775A (zh) * 2021-11-11 2024-08-16 建新公司 作为ripk1抑制剂的异噁唑烷及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI648273B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
WO2016027253A1 (en) 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
CN107108492B (zh) 2014-12-24 2021-03-19 北京生命科学研究所 细胞坏死抑制剂
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
EP3366684B1 (en) 2015-10-23 2020-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10709692B2 (en) 2015-12-04 2020-07-14 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
CN109071504B (zh) 2016-02-05 2022-03-08 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
TW201831464A (zh) 2016-11-18 2018-09-01 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
CR20190566A (es) 2017-05-17 2020-06-14 Denali Therapeutics Inc Inhibidores de quinasay usos de los mismos
RU2020115915A (ru) 2017-10-31 2021-12-01 Ф. Хоффманн-Ля Рош Аг Бициклические сульфоны и сульфоксиды и способы их применения
JP2021509113A (ja) 2017-12-29 2021-03-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としての複素環式アミド
CN112074519B (zh) 2018-04-20 2024-08-02 豪夫迈·罗氏有限公司 作为rip1激酶抑制剂用于治疗例如肠易激综合征(ibs)的化合物
CN110872285A (zh) 2018-08-31 2020-03-10 宁波文达医药科技有限公司 作为受体相互作用蛋白1(rip1)激酶抑制剂的杂环化合物
KR20200087922A (ko) 2019-01-11 2020-07-22 보로노이바이오 주식회사 (3-페닐이속사졸리딘-2-일)(피페리딘-4-일)메타논 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
CN118510775A (zh) * 2021-11-11 2024-08-16 建新公司 作为ripk1抑制剂的异噁唑烷及其用途

Also Published As

Publication number Publication date
US11897876B2 (en) 2024-02-13
US20240109882A1 (en) 2024-04-04
EP4430037A1 (en) 2024-09-18
KR20240099451A (ko) 2024-06-28
AU2022388696A1 (en) 2024-06-27
US20230203027A1 (en) 2023-06-29
MX2024005777A (es) 2024-07-19
CN118510775A (zh) 2024-08-16
CA3237975A1 (en) 2023-05-19
IL312739A (en) 2024-07-01
WO2023083847A1 (en) 2023-05-19
AR127640A1 (es) 2024-02-14
TW202340182A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
CO2018010504A2 (es) Inhibidores del enlace proteína-proteína de wdr5
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2017011851A2 (es) Compuestos novedosos
CO2024007013A2 (es) Isoxazolidinas como inhibidores de ripk1 y uso de estas
CL2018002516A1 (es) Inhibidores de mcl-1 indólicos sustituidos.
BR112021018303A2 (pt) Novos inibidores de pequenas moléculas de fatores de transcrição tead
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
CL2018001897A1 (es) Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509)
CL2020001797A1 (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas.
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
HN2010001761A (es) Derivados de azetidina y ciclobutano como inhibidores de jak
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
BR112018075736A2 (pt) composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
CL2021001209A1 (es) Constructos de suministro para transcitosis y métodos relacionados
DOP2020000072A (es) Amidas de imidazopiridina sustituidas y su uso
CO2022000481A2 (es) Inhibidores de enzimas
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
DOP2017000244A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?